blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2626372

EP2626372 - Bispecific antibodies and methods for production thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.01.2019
Database last updated on 09.09.2024
FormerThe patent has been granted
Status updated on  16.02.2018
FormerGrant of patent is intended
Status updated on  03.10.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V / DK
[2018/03]
Former [2013/33]For all designated states
Genmab A/S
Bredgade 34
1260 Copenhagen K / DK
Inventor(s)01 / Schuurman, Janine
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
02 / Vink, Tom
Schaepmanstraat 25
2406 DB, Alphen aan den Rijn / NL
03 / Winkel, Jan Van De
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
04 / Labrijn, Aran Frank
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
05 / Aalberse, Rob
Roosmarijnhof 1
1115-DV Duivendrecht / NL
06 / Kolfschoten, Marijn van der Neut
Derde Oosterparkstraat 29-hs
1091-JT Amsterdam / NL
07 / Parren, Paul
Werdorperwaard 17
3984 PR Odijk / NL
 [2018/12]
Former [2013/33]01 / Schuurman, Janine
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
02 / Vink, Tom
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
03 / Winkel, Jan Van De
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
04 / Labrijn, Aran Frank
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
05 / Aalberse, Rob
Roosmarijnhof 1
1115-DV Duivendrecht / NL
06 / Kolfschoten, Marijn van der Neut
Derde Oosterparkstraat 29-hs
1091-JT Amsterdam / NL
07 / Parren, Paul
Genmab B.V.
c/o Genmab B.V.
Yalelaan 60
3584-CM Utrecht / NL
Representative(s)Genmab A/S
Carl Jacobsens Vej 30
2500 Valby / DK
[N/P]
Former [2018/12]Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V / DK
Former [2013/33]Genmab A/S
Bredgade 34 E
1260 Copenhagen K / DK
Application number, filing date12199117.828.03.2008
[2013/33]
Priority number, dateUS20070920840P29.03.2007         Original published format: US 920840 P
DK2007000049129.03.2007         Original published format: DK 200700491
[2013/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2626372
Date:14.08.2013
Language:EN
[2013/33]
Type: B1 Patent specification 
No.:EP2626372
Date:21.03.2018
Language:EN
[2018/12]
Search report(s)(Supplementary) European search report - dispatched on:EP16.07.2013
ClassificationIPC:C07K16/46, C07K16/28, C07K16/00
[2017/40]
CPC:
C07K16/468 (EP,US); A61P31/00 (EP); A61P35/00 (EP);
C07K16/00 (EP,US); C07K16/2863 (EP,US); C07K16/2887 (EP,US);
C07K2317/24 (EP,US); C07K2317/31 (EP,US); C07K2317/526 (EP,US);
C07K2317/53 (US); C07K2319/00 (EP,US) (-)
Former IPC [2013/33]C07K16/46, C07K16/28
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/12]
Former [2013/33]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL14.02.2014
BA14.02.2014
MK14.02.2014
RS14.02.2014
TitleGerman:Bispezifische Antikörper und Verfahren zu deren Herstellung[2013/33]
English:Bispecific antibodies and methods for production thereof[2013/33]
French:Anticorps bispécifiques et procédés de production de ceux-ci[2013/33]
Examination procedure14.02.2014Examination requested  [2014/13]
21.03.2014Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
27.05.2014Amendment by applicant (claims and/or description)
07.08.2015Despatch of a communication from the examining division (Time limit: M06)
17.02.2016Reply to a communication from the examining division
23.08.2017Cancellation of oral proceeding that was planned for 13.09.2017
13.09.2017Date of oral proceedings (cancelled)
04.10.2017Communication of intention to grant the patent
09.02.2018Fee for grant paid
09.02.2018Fee for publishing/printing paid
09.02.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP08715601.4  / EP2139924
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20080715601) is  29.12.2010
Opposition(s)02.01.2019No opposition filed within time limit [2019/09]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
27.05.2014Request for further processing filed
27.05.2014Full payment received (date of receipt of payment)
Request granted
13.06.2014Decision despatched
Fees paidRenewal fee
22.04.2013Renewal fee patent year 03
22.04.2013Renewal fee patent year 04
22.04.2013Renewal fee patent year 05
11.03.2013Renewal fee patent year 06
12.03.2014Renewal fee patent year 07
10.03.2015Renewal fee patent year 08
10.03.2016Renewal fee patent year 09
10.03.2017Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.03.2008
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
TR21.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
IS21.07.2018
PT23.07.2018
[2020/33]
Former [2020/28]HU28.03.2008
CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
TR21.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2020/16]CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
TR21.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2020/08]CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
LU28.03.2018
MT28.03.2018
BE31.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/26]CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SI21.03.2018
SK21.03.2018
LU28.03.2018
BE31.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/12]CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
LU28.03.2018
BE31.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/08]CY21.03.2018
CZ21.03.2018
DK21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
LU28.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/06]CY21.03.2018
CZ21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
MC21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
LU28.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/04]CY21.03.2018
CZ21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
LU28.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2019/03]CY21.03.2018
CZ21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
PT23.07.2018
Former [2018/50]CY21.03.2018
CZ21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
SK21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/49]CY21.03.2018
EE21.03.2018
FI21.03.2018
HR21.03.2018
IT21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
PL21.03.2018
RO21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/45]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
NL21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/40]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
LV21.03.2018
SE21.03.2018
BG21.06.2018
NO21.06.2018
GR22.06.2018
Former [2018/37]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NO21.06.2018
GR22.06.2018
Former [2018/35]CY21.03.2018
FI21.03.2018
HR21.03.2018
LT21.03.2018
NO21.06.2018
Documents cited:Search[X]DE19859115  (LINDHOFER HORST [DE]) [X] 1-7,13-19,25,26,33,35-37 * page 5, lines 44,45,58 * * page 6, lines 53-60 *;
 [AD]WO02100348  (GENMAB AS [DK], et al) [AD] 1-37 * the whole document *;
 [AD]WO2004035607  (GENMAB AS [DK], et al) [AD] 1-37 * the whole document *;
 [XA]WO2005000899  (BIOGEN IDEC INC [US], et al) [X] 35,36 * abstract * * page 1, lines 21-29 * * page 3, lines 21-28 * * page 7, lines 8-14 * * page 4, lines 3-10 * * page 5, lines 15-17 * * page 7, lines 15-17 * * page 8, lines 26-31 * * page 8, line 32 - page 9, line 4 * * page 9, lines 20-27 * * page 11, lines 10-12 * * page 11, lines 19-26 * [A] 1-34,37;
 [X]WO2005062916  (CENTOCOR INC [US], et al) [X] 1-7,13-19,25,26,35-37 * page 1, line 27 - page 2, line 1 * * page 3, lines 14-22 * * page 13, lines 31-38 * * page 37, lines 17-20 * * page 67, lines 20-25 * * page 54, line 30 - page 56, line 13 * * page 57, lines 24,25 * * sequences 8,9,14,15 * * page 94, lines 16-20 *;
 [XA]WO2006047340  (AMGEN INC [US], et al) [X] 35,36 * page 37, lines 23-27 * * page 26, line 24 - page 27, line 5 * * page 27, lines 6-8 * * page 79, line 21 - page 82, line 18; example 9 * [A] 1-34,37;
 [X]EP1693386  (CHUGAI PHARMACEUTICAL CO LTD [JP]) [X] 1-3,13-15,26,35-37 * paragraph [0065] * * paragraphs [0068] - [0073] *;
 [AP]WO2007059782  (GENMAB AS [DK], et al) [AP] 1-37 * the whole document *;
 [AP]WO2007103112  (ELAN PHARM INC [US], et al) [AP] 1-37* the whole document *;
 [XA]  - SCHUURMAN J ET AL, "Normal human immunoglobulin G4 is bispecific: It has two different antigen-combining sites", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, (19990801), vol. 97, no. 4, ISSN 0019-2805, pages 693 - 698, XP009104479 [X] 35,36 * abstract * [A] 1-34,37

DOI:   http://dx.doi.org/10.1046/j.1365-2567.1999.00845.x
 [XA]  - SCHUURMAN J ET AL, "The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, (20010101), vol. 38, no. 1, ISSN 0161-5890, pages 1 - 8, XP002329378 [X] 35,36 * abstract * * page 7, column L, paragraph 3 * * page 7, column L, paragraph 5 - column R, paragraph 1 * [A] 1-34,37

DOI:   http://dx.doi.org/10.1016/S0161-5890(01)00050-5
 [XA]  - AALBERSE R C ET AL, "IgG4 breaking the rules", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, (20020101), vol. 105, no. 1, ISSN 0019-2805, pages 9 - 19, XP002987706 [X] 35,36 * page 11, column R, paragraph 2 - page 12, column R, paragraph 1 * [A] 1-34,37

DOI:   http://dx.doi.org/10.1046/j.0019-2805.2001.01341.x
 [XP]  - KOLFSCHOTEN MARIJN VAN DER NEUT ET AL, "Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange", SCIENCE, WASHINGTON, DC, (20070901), vol. 317, no. 5844, ISSN 0036-8075, pages 1554 - 1557, XP009104480 [XP] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1126/science.1144603
 [A]  - MERCHANT A MARGARET ET AL, "An efficient route to human bispecific IgG", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (19980701), vol. 16, no. 7, ISSN 1087-0156, pages 677 - 681, XP002141015 [A] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1038/nbt0798-677
 [A]  - AALBERSE R C ET AL, "THE APPARENT MONOVALENCY OF HUMAN IGG4 IS DUE TO BISPECIFICITY", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, XX, XX, (19990201), vol. 118, no. 2-4, ISSN 1018-2438, pages 187 - 189, XP009080024 [A] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1159/000024062
 [A]  - BLOOM J W ET AL, "Intrachain disulfide bond in the core hinge region of human IgG4", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, (19970101), vol. 6, no. 2, ISSN 0961-8368, pages 407 - 415, XP002329379 [A] 1-37 * the whole document *
 [A]  - ANGAL S ET AL, "A SINGLE AMINO ACID SUBSTITUTION ABOLISHES THE HETEROGENEITY OF CHIMERIC MOUSE/HUMAN (IGG4) ANTIBODY", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, (19930101), vol. 30, no. 1, ISSN 0161-5890, pages 105 - 108, XP000770218 [A] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1016/0161-5890(93)90432-B
by applicantWO9203918
 WO9222645
 WO9301227
 WO9425585
 US5545806
 US5545807
 US5569825
 US5625126
 US5633425
 US5661016
 US5733743
 US5741957
 US5750172
 US5756687
 WO9824884
 US5770429
 US5789650
 US5814318
 US5827690
 US5874299
 US5877397
 WO0109187
 WO0114424
 WO0243478
 WO02100348
 WO2004035607
 WO2005062916
    - AALBERSE, R. C.; R. VAN DER GAAG; J. VAN LEEUWEN, "Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4- restricted response", IMMUNOL, (1983), vol. 130, page 722, XP002950400
    - VAN DER ZEE; J. S., P. VAN SWIETEN; R. C. AALBERSE, "Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency", J IMMUNOL, (1986), vol. 137, page 3566
    - SCHUURMAN, J.; R. VAN REE; G. J. PERDOK; H. R. VAN DOORN; K. Y. TAN; R. C. AALBERSE, "Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites", IMMUNOLOGY, (1999), vol. 97, doi:doi:10.1046/j.1365-2567.1999.00845.x, page 693, XP009104479

DOI:   http://dx.doi.org/10.1046/j.1365-2567.1999.00845.x
    - AALBERSE, R. C.; J. SCHUURMAN, "IgG4 breaking the rules", IMMUNOLOGY, (2002), vol. 105, doi:doi:10.1046/j.0019-2805.2001.01341.x, page 9, XP055115132

DOI:   http://dx.doi.org/10.1046/j.0019-2805.2001.01341.x
    - AALBERSE, R. C.; J. SCHUURMAN; R. VAN REE, "The apparent monovalency of human IgG4 is due to bispecificity", INT ARCH ALLERGY IMMUNOL, (1999), vol. 118, doi:doi:10.1159/000024062, page 187, XP009080024

DOI:   http://dx.doi.org/10.1159/000024062
    - SCHUURMAN, J.; G. J. PERDOK; A. D. GORTER; R. C. AALBERSE, "The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds", MOL IMMUNOL, (2001), vol. 38, doi:doi:10.1016/S0161-5890(01)00050-5, page 1, XP002329378

DOI:   http://dx.doi.org/10.1016/S0161-5890(01)00050-5
    - BLOOM, J. W.; M. S. MADANAT; D. MARRIOTT; T. WONG; S. Y. CHAN, "Intrachain disulfide bond in the core hinge region of human IgG4", PROTEIN SCI, (1997), vol. 6, page 407, XP002329379
    - GREGORY, L.; K. G. DAVIS; B. SHETH; J. BOYD; R. JEFFERIS; C. NAVE; D. R. BURTON, "The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies", MOL IMMUNOL, (1987), vol. 24, doi:doi:10.1016/0161-5890(87)90184-2, page 821, XP023683044

DOI:   http://dx.doi.org/10.1016/0161-5890(87)90184-2
    - DENG, L.; D. WYLIE; Y. S. TSAO; B. LARKIN; M. VOLOCH; W. L. LING, "Detection and quantification of the human IgG4 half-molecule, HL, from unpurified cell-culture supernatants", BIOTECHNOL APPL BIOCHEM, (2004), vol. 40, doi:doi:10.1042/BA20030174, page 261, XP009080029

DOI:   http://dx.doi.org/10.1042/BA20030174
    - MARCIN; ZHU, ACTA PHARMACOL SIN., (2005), vol. 26, page 649
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - KOHLER ET AL., NATURE, (1975), vol. 256, page 495
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
    - LONBERG, N. ET AL., NATURE, (1994), vol. 368, pages 856 - 859
    - LONBERG, N., Handbook of Experimental Pharmacology, (1994), vol. 113, pages 49 - 101
    - LONBERG, N.; HUSZAR, D., INTERN. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93
    - HARDING, F., LONBERG, N. ANN. N.Y. ACAD. SCI, (1995), vol. 764, pages 536 - 546
    - TAYLOR, L. ET AL., NUCLEIC ACIDS RESEARCH, (1992), vol. 20, pages 6287 - 6295
    - CHEN, J. ET AL., INTERNATIONAL IMMUNOLOGY, (1993), vol. 5, pages 647 - 656
    - TUAILLON ET AL., J. IMMUNOL., (1994), vol. 152, pages 2912 - 2920
    - TAYLOR, L. ET AL., INTERNATIONAL IMMUNOLOGY, (1994), vol. 6, pages 579 - 591
    - FISHWILD, D. ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 851
    - CHEN ET AL., EMBO J., (1993), vol. 12, pages 821 - 830
    - HOOGENBOOM ET AL., J. MOL. BIOL., (1991), vol. 227, page 381
    - VAUGHAN ET AL., NATURE BIOTECH, (1996), vol. 14, page 309
    - HANES; PLUCTHAU, PNAS USA, (1997), vol. 94, pages 4937 - 4942
    - PARMLEY; SMITH, GENE, (1988), vol. 73, pages 305 - 318
    - SCOTT, TIBS, (1992), vol. 17, pages 241 - 245
    - CWIRLA ET AL., PNAS USA, (1990), vol. 87, pages 6378 - 6382
    - RUSSEL ET AL., NUCL. ACIDS RESEARCH, (1993), vol. 21, pages 1081 - 1085
    - HOOGENBOOM ET AL., IMMUNOL. REVIEWS, (1992), vol. 130, pages 43 - 68
    - CHISWELL; MCCAFFERTY, TIBTECH, (1992), vol. 10, pages 80 - 84
    - MERCHANT ET AL., NATURE BIOTECH, (1998), vol. 16, pages 677 - 681
    - AKKERDAAS, VAN REE ET AL., ALLERGY, (1995), vol. 50, no. 3, pages 215 - 220
    - DE GROOT ET AL., J. ALLERGY CLIN. IMMUNOL., (1988), vol. 82, page 778
    - LAEMMLI, NATURE, (1970), vol. 227, no. 5259, pages 680 - 5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.